about
The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future PossibilitiesGlobal myocardial strain assessment by different imaging modalities to predict outcomes after ST-elevation myocardial infarction: A systematic review'A one-sided affair': unilateral pulmonary oedema and the role of cardiac MRI in diagnosing premature coronary artery disease in a patient with Prader-Willi syndromeNoncardiac chest pain in a patient with cardiac pathology: the importance of an accurate historyPrevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction.The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised cPredictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): a prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease.A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction.Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths.Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance.Effect of late sodium current inhibition on MRI measured diastolic dysfunction in aortic stenosis: a pilot study.Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis PatientsThe haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans?Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial.Comparison of global myocardial strain assessed by cardiovascular magnetic resonance tagging and feature tracking to infarct size at predicting remodelling following STEMINon-invasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment.Stress cardiovascular MR in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings.Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?A novel surface electrocardiogram-based marker of ventricular arrhythmia risk in patients with ischemic cardiomyopathyComplete Versus Lesion-Only Primary PCI: The Randomized Cardiovascular MR CvLPRIT SubstudyDesign and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease.Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysisInfarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.Assessment of valve haemodynamics, reverse ventricular remodelling and myocardial fibrosis following transcatheter aortic valve implantation compared to surgical aortic valve replacement: a cardiovascular magnetic resonance study.Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).Investigating the effects of 6 months extended duration, in-centre nocturnal versus conventional haemodialysis treatment: a non-randomised, controlled feasibility studyCan cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?Dressler's syndrome demonstrated by late gadolinium enhancement cardiovascular magnetic resonance.Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study.Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations.Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography.Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients.Natriuretic peptides in common valvular heart disease.Revascularization in patients with chronic ischaemic myocardial dysfunction: insights from cardiovascular magnetic resonance imaging.Advances in the understanding of the pathophysiology and management of aortic stenosis: role of novel imaging techniques.Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
P50
Q27000396-2DBCAC61-65AB-4AA8-8D82-93A7421BDB4DQ30360334-507EC0C7-A895-4F7D-97DC-9850447311FEQ30394554-8EB50B40-0CD4-463B-A47F-52AC0386094CQ30411080-8B819717-3CBB-455B-93FE-B0C9AED5EE03Q33576596-62B99571-E7C0-44B0-9FE9-553AE688133BQ33700648-7E77684D-F59D-415A-964D-A3833F370451Q34305843-87C92432-64D7-494C-A593-874639D79932Q34571112-06192475-C10B-4A13-A7F3-68886F02CF6FQ34776019-C7502BAF-8847-42C9-8583-7285AD5CE85AQ34962538-5EF87FE1-AF3D-4892-8E5D-31FAC42C95C6Q35141223-1B421A6C-E6F5-4F9C-9B07-3A043A0FED93Q35175453-15515B40-F843-48B8-B64E-47A392DE3A2FQ35415343-FD932DE4-AAE9-4A36-8B95-69D241099D68Q35915087-72C95D28-181A-4291-A6BF-53A227B708ACQ35922682-F3C0BBC3-4ADF-4352-99D2-D283E855E14CQ36053195-370E9EF1-2B41-4A84-9D9B-55B761C4D647Q36071494-E46D1196-7F13-4A13-A6BB-44545343ECFBQ36240772-F31F44FC-E845-4879-AEAD-D38F04584836Q36325459-47CD0C86-B668-4785-B3A4-4FE280776CF1Q36325926-C67BAE5D-A531-4CA6-BCED-4285EB5A8F5FQ36340957-D7B5C136-4CD6-44FA-92A5-87B91466A1B9Q36366302-0AE412CA-B37A-48B0-95A1-F7445BA410A3Q36378795-5ABB389F-1EE5-4DF0-813A-5869C7104E30Q36498991-EB094048-D679-4A3A-92B4-7960034FA06BQ37030536-CF94DF08-C547-426D-9D76-2DC98764C98BQ37053525-8401A118-6A11-4765-A82B-B0A083742F9BQ37076189-822BE726-5BE2-436F-809A-20718B07A553Q37105484-42FBF2BF-7BA5-411A-ABFE-EEDD25A519CBQ37113253-73FC68E8-2C27-45EE-96E6-EB763CAAF6D0Q37251682-8E067140-B4B5-428C-BC5A-C94280DF15B0Q37287532-D64C8510-E959-461D-86A5-891AAC07BC33Q37295337-015F3508-D7C1-42E4-802F-3AA33FF60A95Q37414864-D7197CA1-D9B4-45EC-A392-248B7EDE8068Q37448642-B236048F-8526-4134-8B3D-1E0106B8B2C4Q37524613-766F64A1-BF2C-47F9-AD60-42FB130EC7A8Q37668262-026231DC-18C9-4AF9-967C-D6B14BD8B07DQ37743962-7564AEB0-4692-4252-84A4-C41E41458A4AQ38049298-CC93C88A-BA14-4DCB-B7C2-A237EF36E4D8Q38228582-21FFF725-940A-4FBD-AA65-03BCDF145501Q38388280-79D62E13-4071-40C4-B6F4-42D7C8A836C9
P50
description
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Gerry P McCann
@ast
Gerry P McCann
@en
Gerry P McCann
@en-gb
Gerry P McCann
@es
Gerry P McCann
@nl
Gerry P McCann
@sl
type
label
Gerry P McCann
@ast
Gerry P McCann
@en
Gerry P McCann
@en-gb
Gerry P McCann
@es
Gerry P McCann
@nl
Gerry P McCann
@sl
prefLabel
Gerry P McCann
@ast
Gerry P McCann
@en
Gerry P McCann
@en-gb
Gerry P McCann
@es
Gerry P McCann
@nl
Gerry P McCann
@sl
P106
P21
P31
P496
0000-0002-5542-8448